source
- Johnson & Johnson shares drop 6% after earnings meet forecasts but show weak medical device outlookJohnson & Johnson reported third‑quarter results that met Wall Street expectations and raised its 2026 financial guidance, yet the stock fell about 6% on the day. Analysts highlighted an underwhel…
- Verastem’s experimental KRAS drug shows early promise in small study, shares jump 18%Verastem Oncology announced early data from a small study of its experimental drug VS-7375, which targets the KRAS G12D mutation. The study enrolled patients with metastatic pancreatic ductal aden…